ToplinePharma titan Eli Lilly on Thursday reported strong demand for its weight loss and diabetes drugs Zepbound and Mounjaro, smashing analysts’ expectations in the face of growing competition in the lucrative weight loss drug market as it struggles to boost supplies and tackle shortages.Eli Lilly has struggled to keep up with demand for its weight loss and diabetes drug tirzepatide.Getty Images Key FactsEli Lilly reported $11.3 billion in revenue and$2.97 billion in net profit for the second quarter of 2 ...